Ironwood Pharma (IRWD) Posts Q1 Loss of 38c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Aegis Maintains Ironwood Pharma (IRWD) at Buy; Still Positive on LINZESS Amid Slower Start
April 29, 2014 12:02 PM EDTAegis Capital reaffirms its Buy rating and $16 target price on Ironwood Pharmaceuticals (Nasdaq: IRWD) following the company's Q1 report. Ahead of the bell, Ironwood posted Q1 loss of $.38 per share with revenue of $14.6 million, versus consensus estimates looking for a loss of $.44 per share with revenue of $8.52 million.
Analyst Ram Selvaraju commented, On its earnings conference call,... More
